Auf dieser Website kommen Cookies zum Einsatz. Für weitere Informationen über Cookies, klicken Sie bitte auf den Link Datenschutz. Wenn Sie „Ok“ klicken und die Website weiter nutzen, gehen wir von Ihrem Einverständnis aus.

Cookies are used on this website. For more information about cookies, please click on the Privacy Policy link. If you click on "Ok" and continue to use the website, we assume your agreement.

11th Biotech Press-Lounge

Top researchers met industry experts at the IZB

Sebastian Grabert, Director – Germany Representative, EURONEXT N.V., Dr. Martin Laqua, Senior Editor, Transkript, Dr. Michael Almstetter, CEO, Origenis GmbH, Prof. Dr. Dr. h.c. Bruno Reichart, Ehemaliger Herzchirurg, Co-Sprecher DFG Transregio Xenotransplantation, Klinikum der Universität München, Dr. Joachim Vogt, Director Search and Evaluation (S&E), Western Europe, AbbVie Deutschland GmbH & Co. KG, Dr. Peter Hanns Zobel, Geschäftsführer, Fördergesellschaft IZB mbH (v.l.n.r.)

 

Are heart transplants with genetically modified pig hearts within reach? How can the advances in oncology also open up new therapies for Alzheimer's and Parkinson's disease? What opportunities exist for partnering with a biopharmaceutical company? And how can the stock markets strengthen the European life sciences sector?

At the eleventh Biotech Press Lounge on May 16, 2019, four speakers addressed 100 participants: Prof. Dr. Dr. h.c. Bruno Reichart of the clinic of the University Munich, Dr. med. ­Michael Almstetter, Managing Director of Origenis GmbH, Dr. Ing. Joachim Vogt, Director of Search and Evaluation (S&E), Western Europe at AbbVie Germany GmbH & Co. KG, and Sebastian Grabert, Germany representative of Euronext N.V. Dr. Martin Laqua, senior editor at Transcript, led the program. He first announced Prof. Reichart, who spoke about the long-term success of heart transplants with genetically modified pig hearts. The organs of genetically modified (xenogeneic) pigs are a promising alternative for terminally ill patients. He was followed by Dr. Michael Almstetter, who explained how advances in oncology can be used to develop new treatments for Alzheimer's and Parkinson's disease. Dr. Joachim Vogt presented cooperation opportunities with AbbVie and emphasized the importance of cooperation for the success of medical research. Finally, the 100 attendees learned from Sebastian Grabert, Germany representative of Euronext N.V., how the stock markets can strengthen the life sciences ­sector. The task of the stock exchanges is to provide companies access to industry-specific as well as generalist-oriented investors worldwide. Following the talks the speakers engaged in intensive exchange of ideas and networking with the participants of the event.

View PDF

Go back